Pruritus, or chronic itch, is a debilitating symptom central to numerous dermatological and systemic diseases, yet it remains one of the most challenging endpoints to assess in preclinical research. To address this, Prisys Biotech has developed a sophisticated and highly translational non-human primate (NHP) pruritus model, providing a robust platform to accurately evaluate the efficacy of novel anti-itch therapies.
A Clinically Relevant Model: IL-31-Induced Pruritus in Cynomolgus Monkeys
Our model utilizes cynomolgus monkeys, whose immunological and neurological pathways closely mirror those of humans, ensuring high clinical relevance.
Targeted Induction: Pruritus is induced via the targeted administration of cynomolgus IL-31 (cyIL-31). As a key pro-inflammatory cytokine linked to Th1, Th2, and Th17 immune responses, IL-31 is a clinically validated driver of itch in human conditions like atopic dermatitis (AD) and asthma. This targeted induction creates a model with a clear, translatable mechanism of action.
Disease Correlation: This model is intrinsically linked to allergic diseases. By focusing on IL-31, our platform is ideal for investigating therapeutics intended for AD and asthma, where pruritus is a primary and distressing symptom.
Beyond Observation: AI-Powered Behavioral Analysis with Prisys BehaviorAtlas
Subjectivity in behavioral assessment can be a major variable in preclinical studies. Prisys Biotech overcomes this challenge with our innovative, AI-driven Prisys BehaviorAtlas System, which transforms behavioral observation into objective, quantitative data.
Precision Quantification: Using high-definition cameras for 3D motion capture and skeletal reconstruction, the system precisely monitors and analyzes scratching behavior without human bias.
In-Depth Metrics: We provide detailed, actionable data points crucial for evaluating therapeutic efficacy, including:
- Total count and duration (in seconds) of scratching events.
- Time-course analysis of behavior at defined intervals post-stimulation.
- Classification of scratching bouts by duration (e.g., short-duration vs. long-duration).
Deep Insights: This level of detail allows for a nuanced understanding of a drug's effect on both the immediate urge to scratch and sustained pruritic states.
A Proven Platform for Validating Therapeutic Efficacy
The ultimate goal of a preclinical model is to predict clinical success. The Prisys Biotech pruritus model is specifically designed to assess the therapeutic potential of test articles in inhibiting IL-31-induced scratching.
Our studies have successfully demonstrated that treatment with test articles can lead to a significant and measurable inhibition of scratching behaviors in this model. This provides our partners with clear, robust efficacy data to support critical decision-making and advance their most promising candidates with confidence.
Conclusion: Accelerate Your Anti-Pruritic Pipeline
By combining a clinically relevant induction method with state-of-the-art, AI-powered behavioral quantification, the Prisys Biotech NHP pruritus model offers unparalleled precision and reliability. We provide the critical data needed to de-risk development and accelerate the journey of novel anti-itch therapies from the lab to the clinic.
Ready to objectively measure the efficacy of your anti-pruritic compound? Contact us today to learn how our advanced NHP models can empower your research.
